Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 Tislelizumab vs Sorafenib in First-Line Unresectable Hepatocellular Carcinoma
2017-002423-19Phase 3Unknown
- Sponsor
- BeiGene
- Start
- Nov 2017
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of tislelizumab in hepatocellular carcinoma (HCC) (2 arms), sponsored by BeiGene. Primary endpoint: Overall survival. Status: unknown.
02
Drugs
tislelizumab
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on 2017-002423-19.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-002423-19.